Becker Private Equity & Business Podcast: Novo Nordisk & Excess Profits

Episode: Novo Nordisk & Excess Profits
Host: Scott Becker
Release Date: July 29, 2025

Introduction

In this episode of the Becker Private Equity & Business Podcast, host Scott Becker delves into the financial dynamics surrounding Novo Nordisk, a leading pharmaceutical company. The discussion centers on the concept of excess profits, their sustainability, and the competitive pressures Novo Nordisk is currently facing. This episode offers valuable insights for investors, business professionals, and enthusiasts interested in the private equity landscape and the pharmaceutical industry's economic intricacies.

Understanding Excess Profits in Business

Scott Becker opens the conversation by defining the fundamental business principle related to excess profits:

"If there's any time that you're in a business that's hitting excess profits... then at some point people are going to come after those profits in different ways." ([00:30])

Becker emphasizes that excess profits, while indicative of a company's strong performance, often attract attention from competitors and other market players aiming to capitalize on or undermine that profitability. He cites Novo Nordisk and Eli Lilly as prime examples of companies that have experienced sustained periods of excess profits, making them targets for competitive actions.

Novo Nordisk's Current Financial Challenge

Becker transitions into a detailed analysis of Novo Nordisk's recent financial struggles:

"Novo Nordisk is no exception to that... they've cut their expected full-year sales growth to 8 to 14%, down from 20% or so." ([01:15])

This significant reduction in sales growth forecasts highlights the intense competitive environment Novo Nordisk is navigating. The host points out that such a drastic adjustment signals underlying challenges that could affect investor confidence and market performance.

Impact on Stock Performance

Addressing the repercussions of the revised sales forecasts, Becker discusses the impact on Novo Nordisk's stock:

"Their stock has fallen about 20% today... more than 20% today." ([02:00])

The sharp decline in stock price underscores the market's reaction to the company's lowered growth expectations. Furthermore, he notes that over the past year, Novo Nordisk's stock has plummeted by over 50%, a clear indicator of sustained investor concern amidst increasing competition.

Competition and Market Pressures

A significant portion of the episode is dedicated to analyzing the competitive landscape affecting Novo Nordisk:

"They're facing increased competition from others like Hims and Hers and Eli Lilly and others." ([03:00])

Becker identifies Hims and Hers and Eli Lilly as key competitors encroaching on Novo Nordisk's market share, particularly in the weight loss drug segment. He elaborates on how these competitors are eroding the market dominance that Novo Nordisk once enjoyed, notably with their flagship weight loss drug, Wegovy.

Sustainability of Excess Profits

Returning to the central theme, Becker reflects on the sustainability of excess profits:

"If you're making excess profits, you better figure out if they're sustainable or not." ([04:15])

He cautions businesses and investors alike to critically assess the longevity of excess profits, considering factors such as market saturation, emerging competitors, and regulatory changes. The case of Novo Nordisk serves as a cautionary tale of how quickly market dynamics can shift, turning profitable ventures into challenging endeavors.

Strategic Responses and Future Outlook

In concluding his analysis, Becker discusses possible strategic responses for Novo Nordisk:

"As in all businesses, if you're making excess profits, you better figure out if they're sustainable or not... they're aggressively cutting their forecast." ([05:30])

He suggests that Novo Nordisk may need to innovate further, diversify its product portfolio, or enhance its competitive strategies to regain and sustain its profitability. The host also highlights the importance of risk management, advising businesses to prepare for volatility even during periods of apparent success.

Conclusion

Scott Becker wraps up the episode with a succinct takeaway:

"If it's going too well, it's likely going too well and you better do risk at some point." ([06:00])

This final thought serves as a reminder that in the business world, sustained success is often met with increased scrutiny and competition. Companies must remain vigilant and adaptable to maintain their market positions and financial health.

Key Takeaways

• Excess Profits Attract Competition: Companies experiencing high profits are often targeted by competitors aiming to capture a share of the market.

• Novo Nordisk's Decline: Recent cuts in sales growth forecasts and a substantial drop in stock price indicate significant challenges for Novo Nordisk.

• Intensifying Competition: Rivals like Hims and Hers and Eli Lilly are increasingly competitive, impacting Novo Nordisk's market dominance.

• Sustainability is Crucial: Businesses must continuously evaluate the sustainability of their profits amidst changing market conditions.

• Strategic Adaptation Needed: To counteract competitive pressures, companies like Novo Nordisk may need to innovate and diversify their strategies.

Final Thoughts

This episode of the Becker Private Equity & Business Podcast provides a comprehensive analysis of Novo Nordisk's current financial woes within the broader context of excess profits and market competition. Scott Becker offers a nuanced perspective on the fragility of profitability and the perpetual vigilance required to sustain business success. Listeners gain valuable lessons on the interplay between market forces and corporate strategy, applicable across various sectors and industries.

For more insightful discussions on private equity and business trends, tune into future episodes of the Becker Private Equity & Business Podcast.